M. Schlemmer

5.5k total citations · 1 hit paper
64 papers, 3.2k citations indexed

About

M. Schlemmer is a scholar working on Pulmonary and Respiratory Medicine, Gastroenterology and Surgery. According to data from OpenAlex, M. Schlemmer has authored 64 papers receiving a total of 3.2k indexed citations (citations by other indexed papers that have themselves been cited), including 47 papers in Pulmonary and Respiratory Medicine, 27 papers in Gastroenterology and 19 papers in Surgery. Recurrent topics in M. Schlemmer's work include Sarcoma Diagnosis and Treatment (30 papers), Gastrointestinal Tumor Research and Treatment (27 papers) and Gastric Cancer Management and Outcomes (18 papers). M. Schlemmer is often cited by papers focused on Sarcoma Diagnosis and Treatment (30 papers), Gastrointestinal Tumor Research and Treatment (27 papers) and Gastric Cancer Management and Outcomes (18 papers). M. Schlemmer collaborates with scholars based in Germany, France and Italy. M. Schlemmer's co-authors include Jean‐Yves Blay, Paolo G. Casali, Peter Reichardt, Jaap Verweij, Ian Judson, M. van Glabbeke, Peter Hohenberger, John Zalcberg, Allan T. van Oosterom and Raf Sciot and has published in prestigious journals such as Journal of Clinical Oncology, Cancer and Clinical Cancer Research.

In The Last Decade

M. Schlemmer

63 papers receiving 3.1k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

KIT mutations and dose selection for imatinib in patients with advanced gastrointestinal stromal tumours

2006 654 citations M. Schlemmer, Peter Hohenberger et al. European Journal of Cancer profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
M. Schlemmer Germany	26	2.2k	2.0k	1.2k	557	520	64	3.2k
Pekka Tervahartiala Finland	24	1.5k 0.7×	1.0k 0.5×	1.1k 0.9×	321 0.6×	245 0.5×	68	3.1k
Sonja E. Steigen Norway	25	1.4k 0.6×	1.4k 0.7×	1.1k 0.9×	524 0.9×	211 0.4×	55	2.5k
Kirsten Sundby Hall Norway	32	2.4k 1.1×	736 0.4×	1.1k 0.9×	988 1.8×	515 1.0×	103	3.4k
A. Kevin Raymond United States	22	1.6k 0.7×	805 0.4×	637 0.5×	632 1.1×	251 0.5×	52	2.4k
Beatrice Seddon United Kingdom	29	2.4k 1.1×	441 0.2×	662 0.5×	1.2k 2.2×	202 0.4×	74	3.4k
Inga‐Marie Schaefer United States	26	1.2k 0.6×	330 0.2×	536 0.4×	536 1.0×	515 1.0×	80	2.5k
Man H. Shiu United States	32	2.3k 1.0×	466 0.2×	1.1k 0.9×	1.6k 2.8×	491 0.9×	56	3.6k
Federica Bertolini Italy	28	946 0.4×	297 0.1×	931 0.7×	1.2k 2.1×	154 0.3×	120	2.2k
Thor Alvegård Sweden	33	2.7k 1.2×	377 0.2×	837 0.7×	1.6k 2.9×	172 0.3×	81	3.3k
Antonio López–Pousa Spain	32	1.9k 0.8×	264 0.1×	804 0.6×	1.7k 3.0×	131 0.3×	161	3.4k

Countries citing papers authored by M. Schlemmer

Since Specialization

Citations

This map shows the geographic impact of M. Schlemmer's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by M. Schlemmer with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites M. Schlemmer more than expected).

Fields of papers citing papers by M. Schlemmer

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by M. Schlemmer. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by M. Schlemmer. The network helps show where M. Schlemmer may publish in the future.

Co-authorship network of co-authors of M. Schlemmer

This figure shows the co-authorship network connecting the top 25 collaborators of M. Schlemmer. A scholar is included among the top collaborators of M. Schlemmer based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with M. Schlemmer. M. Schlemmer is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Vogel, Christina, Börje Ljungberg, Karim Bensalah, et al.. (2018). Imaging in Suspected Renal-Cell Carcinoma: Systematic Review. Clinical Genitourinary Cancer. 17(2). e345–e355. 54 indexed citations

Joensuu, Heikki, Mikael Eriksson, Kirsten Sundby Hall, et al.. (2015). Adjuvant Imatinib for High-Risk GI Stromal Tumor: Analysis of a Randomized Trial. Journal of Clinical Oncology. 34(3). 244–250. 149 indexed citations

Schlemmer, M., U. Suchner, Barbara Schäpers, et al.. (2015). Is glutamine deficiency the link between inflammation, malnutrition, and fatigue in cancer patients?. Clinical Nutrition. 34(6). 1258–1265. 29 indexed citations

Reichardt, Peter, Jean‐Yves Blay, Hans Gelderblom, et al.. (2012). Phase III study of nilotinib versus best supportive care with or without a TKI in patients with gastrointestinal stromal tumors resistant to or intolerant of imatinib and sunitinib. Annals of Oncology. 23(7). 1680–1687. 97 indexed citations

Wegener, Bernd, M. Schlemmer, Hans‐Joachim Stemmler, et al.. (2012). Analysis of orthopedic surgery of bone metastases in breast cancer patients. BMC Musculoskeletal Disorders. 13(1). 232–232. 23 indexed citations

Benesch, Martin, Ivo Leuschner, Eva Wardelmann, et al.. (2011). Gastrointestinal stromal tumours in children and young adults: A clinicopathologic series with long-term follow-up from the database of the Cooperative Weichteilsarkom Studiengruppe (CWS). European Journal of Cancer. 47(11). 1692–1698. 14 indexed citations

Joensuu, Heikki, Mats Eriksson, Kirsten Sundby Hall, et al.. (2011). Twelve versus 36 months of adjuvant imatinib (IM) as treatment of operable GIST with a high risk of recurrence: Final results of a randomized trial (SSGXVIII/AIO).. Journal of Clinical Oncology. 29(18_suppl). LBA1–LBA1. 36 indexed citations

Schlemmer, M., Sebastian Bauer, J.T. Hartmann, et al.. (2011). Activity and side effects of imatinib in patients with gastrointestinal stromal tumors: data from a german multicenter trial. European journal of medical research. 16(5). 206–206. 25 indexed citations

Geiger, Sandra, M. Schlemmer, Volker Heinemann, & Hans‐Joachim Stemmler. (2010). Adjuvant cisplatin-based chemotherapy for resected NSCLC: one size fits all?. Anti-Cancer Drugs. 21(9). 799–804. 10 indexed citations

10.

Schlemmer, M., Clemens-M. Wendtner, Lars H. Lindner, et al.. (2010). Thermochemotherapy in patients with extremity high-risk soft tissue sarcomas (HR-STS). International Journal of Hyperthermia. 26(2). 127–135. 10 indexed citations

11.

Schlemmer, M., Steven Sourbron, Konstantin Nikolaou, et al.. (2009). Perfusion patterns of metastatic gastrointestinal stromal tumor lesions under specific molecular therapy. European Journal of Radiology. 77(2). 312–318. 24 indexed citations

12.

Thalheimer, Andreas, M. Schlemmer, Marco Bueter, et al.. (2008). Familial Gastrointestinal Stromal Tumors Caused by the Novel KIT Exon 17 Germline Mutation N822Y. The American Journal of Surgical Pathology. 32(10). 1560–1565. 24 indexed citations

13.

Schlemmer, M., Peter Reichardt, Jaap Verweij, et al.. (2007). Paclitaxel in patients (pts) with advanced angiosarcomas. Journal of Clinical Oncology. 25(18_suppl). 10033–10033. 3 indexed citations

14.

Schlemmer, M.. (2005). Desmoid Tumors and Deep Fibromatoses. Hematology/Oncology Clinics of North America. 19(3). 565–571. 54 indexed citations

15.

Zalcberg, John, Jaap Verweij, Paolo G. Casali, et al.. (2005). Outcome of patients with advanced gastro-intestinal stromal tumours crossing over to a daily imatinib dose of 800mg after progression on 400mg. European Journal of Cancer. 41(12). 1751–1757. 281 indexed citations

16.

Hentrich, Marcus, Daniel Oruzio, Gundula Jäger, et al.. (2004). Impact of human herpesvirus‐6 after haematopoietic stem cell transplantation. British Journal of Haematology. 128(1). 66–72. 108 indexed citations

17.

Schlemmer, M., Peter Hohenberger, Peter Wust, et al.. (2004). First interim report on the randomized EORTC 62961/ESHO-RHT 95 Intergroup Study (phase III) combined with regional hyperthermia (RHT) versus chemotherapy alone in the treatment of high-risk soft tissue sarcomas (HR-STS) in adults. Journal of Clinical Oncology. 22(14_suppl). 9015–9015. 7 indexed citations

18.

Schlemmer, M., et al.. (2003). Gastrointestinal stromal tumors. DMW - Deutsche Medizinische Wochenschrift. 128(39). 2015–2019. 6 indexed citations

19.

Issels, Rolf D. & M. Schlemmer. (2002). Current trials and new aspects in soft tissue sarcoma of adults. Cancer Chemotherapy and Pharmacology. 49(0). 4–8. 21 indexed citations

20.

Firbas, W., H Sinzinger, & M. Schlemmer. (1973). [Circulus arteriosus of the rat, mouse and golden hamster].. PubMed. 2(3). 243–51. 4 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact